Upcoming Dividend • Apr 27
Upcoming dividend of €0.15 per share Eligible shareholders must have bought the stock before 04 May 2026. Payment date: 06 May 2026. Trailing yield: 4.3%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (2.2%). New Risk • Apr 12
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Minor Risks Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.4m market cap, or US$23.9m). Declared Dividend • Mar 30
Dividend increased to €0.15 Dividend of €0.15 is 15% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 5.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 27% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Anuncio • Mar 28
Arterra Bioscience S.p.A. announces Annual dividend, payable on May 06, 2026 Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1500 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026. Anuncio • Jan 21
Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million. Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million on January 20, 2026. A cash consideration valued at €3.2 per share will be paid by Smart Capital S.p.A. Following the transaction, which took place outside the market, Smart Capital will hold 799,500 shares, thus increasing its stake from 5.00% to 12.01% of Arterra's share capital.
Smart Capital S.p.A. (BIT:SMCAP) completed the acquisition of an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) on January 20, 2026. New Risk • Oct 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.8m market cap, or US$24.2m). Valuation Update With 7 Day Price Move • Oct 08
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to €3.32, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total returns to shareholders of 114% over the past three years. New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (217% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€17.0m market cap, or US$19.8m). New Risk • May 22
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 289% Dividend yield: 5.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (289% cash payout ratio). Market cap is less than US$100m (€15.6m market cap, or US$17.6m). Upcoming Dividend • Apr 28
Upcoming dividend of €0.13 per share Eligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Trailing yield: 5.5%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.9%). New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.6m revenue, or US$4.2m). Market cap is less than US$100m (€14.9m market cap, or US$17.0m). Buy Or Sell Opportunity • Apr 07
Now 27% overvalued after recent price rise Over the last 90 days, the stock has risen 4.9% to €2.16. The fair value is estimated to be €1.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Anuncio • Apr 07
Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025 Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025, at 11:00 W. Europe Standard Time. Location: via benedetto brin n 69 Italy Declared Dividend • Mar 31
Dividend increased to €0.13 Dividend of €0.13 is 30% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 6.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 26% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 31% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years. Anuncio • Mar 30
Arterra Bioscience S.p.A. announces Annual dividend, payable on May 07, 2025 Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1300 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025. Reported Earnings • Oct 06
First half 2024 earnings released First half 2024 results: Revenue: €2.56m (up 14% from 1H 2023). Net income: €517.3k (up 108% from 1H 2023). Profit margin: 20% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Reported Earnings • Jun 28
Full year 2023 earnings released Full year 2023 results: Revenue: €4.72m (down 1.8% from FY 2022). Net income: €1.08m (down 24% from FY 2022). Profit margin: 23% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses. Upcoming Dividend • Apr 29
Upcoming dividend of €0.10 per share Eligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Trailing yield: 5.2%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.8%). New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (€13.0m market cap, or US$13.8m). Reported Earnings • Oct 05
First half 2023 earnings released First half 2023 results: Revenue: €2.25m (down 10% from 1H 2022). Net income: €248.6k (down 63% from 1H 2022). Profit margin: 11% (down from 27% in 1H 2022). The decrease in margin was primarily driven by lower revenue. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €1.64, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 44% over the past three years. Buying Opportunity • Sep 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 27%. The fair value is estimated to be €2.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Upcoming Dividend • May 01
Upcoming dividend of €0.10 per share at 4.0% yield Eligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 4.0%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.4%). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Counselor Lucio Annunziato was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 02
First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021) First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €2.51m (up 14% from 1H 2021). Net income: €678.7k (up 74% from 1H 2021). Profit margin: 27% (up from 18% in 1H 2021). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 19
Full year 2021 earnings released Full year 2021 results: Revenue: €4.74m (up 14% from FY 2020). Net income: €1.11m (flat on FY 2020). Profit margin: 23% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorated over the past week After last week's 20% share price decline to €2.00, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 33% over the past year. Reported Earnings • Oct 03
First half 2021 earnings released The company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: €2.21m (up 40% from 1H 2020). Net income: €390.6k (up 13% from 1H 2020). Profit margin: 18% (down from 22% in 1H 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Jun 13
Full year 2020 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €4.17m (up 19% from FY 2019). Net income: €1.11m (up 29% from FY 2019). Profit margin: 27% (up from 24% in FY 2019). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 23% share price gain to €4.08, the stock trades at a trailing P/E ratio of 46.8x. Average forward P/E is 35x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year. Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improved over the past week After last week's 20% share price gain to €3.41, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 32.7x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total return to shareholders over the past year is a loss of 7.8%. Is New 90 Day High Low • Jan 08
New 90-day high: €3.41 The company is up 15% from its price of €2.96 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: €2.80 The company is down 2.0% from its price of €2.87 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period.